Salvador Algarra-Martin

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 15, 2026

Simultaneous Quantification of Multiple Immune Checkpoint Interactions in Melanoma.

Journal: Journal of clinical medicine

Published: May 18, 2026

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Journal: Cancer

Published: November 11, 2025

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

Journal: The Journal of clinical investigation

Published: October 07, 2025

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 06, 2025

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 17, 2025

Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.

Journal: Melanoma research

Published: June 09, 2025

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 26, 2025

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Simultaneous Quantification of Multiple Immune Checkpoint Interactions in Melanoma.

Simultaneous Quantification of Multiple Immune Checkpoint Interactions in Melanoma.

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.

Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.

Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801).

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801).

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis.

Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis.

Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.

Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.

Access to melanoma drugs in Spain: a cross-sectional survey.

Access to melanoma drugs in Spain: a cross-sectional survey.